Stockscreener 앱 받기
72.57
0.07%
0.05
전일 마감가:
$72.52
열려 있는:
$72.59
하루 거래량:
2.65M
Relative Volume:
0.97
시가총액:
$11.38B
수익:
$1.21B
순이익/손실:
$109.52M
주가수익비율:
104.24
EPS:
0.6962
순현금흐름:
$269.60M
1주 성능:
+0.15%
1개월 성능:
+0.33%
6개월 성능:
+26.52%
1년 성능:
+17.81%
1일 변동 폭
$72.45
$72.59
1주일 범위
$72.44
$72.61
52주 변동 폭
$43.20
$72.69
바이오-테크네 Stock (TECH) Company Profile
명칭
Bio Techne Corp
전화
612-379-8854
주소
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
72.57 | 11.38B | 1.21B | 109.52M | 269.60M | 0.6962 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
바이오-테크네 Stock (TECH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-08-13 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2026-06-11 | 개시 | Piper Sandler | Neutral |
| 2026-05-15 | 재개 | RBC Capital Mkts | Outperform |
| 2025-09-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-08-21 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-07-22 | 재개 | Stephens | Overweight |
| 2025-07-09 | 개시 | TD Cowen | Buy |
| 2025-05-30 | 개시 | Wells Fargo | Overweight |
| 2025-04-09 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | 개시 | Evercore ISI | Outperform |
| 2025-02-19 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-02-08 | 개시 | Scotiabank | Sector Outperform |
| 2024-02-02 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-07 | 개시 | UBS | Buy |
| 2023-08-28 | 개시 | William Blair | Outperform |
| 2023-01-10 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-12-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-12-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-04-25 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | 업그레이드 | Stifel | Hold → Buy |
| 2021-01-25 | 재확인 | The Benchmark Company | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | 개시 | Atlantic Equities | Overweight |
| 2020-07-15 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-05-14 | 개시 | The Benchmark Company | Buy |
| 2020-01-08 | 재개 | Stephens | Overweight |
| 2020-01-08 | 개시 | Wells Fargo | Equal Weight |
| 2020-01-07 | 개시 | Citigroup | Neutral |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-07-02 | 업그레이드 | Janney | Neutral → Buy |
| 2019-01-14 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2018-10-17 | 개시 | Goldman | Neutral |
| 2018-06-15 | 개시 | Argus | Buy |
| 2017-07-13 | 개시 | Wells Fargo | Market Perform |
| 2017-02-09 | 개시 | Citigroup | Buy |
| 2017-01-18 | 개시 | Deutsche Bank | Buy |
| 2016-11-10 | 재개 | Leerink Partners | Outperform |
| 2015-01-21 | 재확인 | Robert W. Baird | Outperform |
| 2013-09-20 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
모두보기
바이오-테크네 주식(TECH)의 최신 뉴스
Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development - Investing News Network
Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development - Yahoo Finance
Bio-Techne Company Profile & Introduction - Moomoo
INCY or TECH: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Robert V Baumgartner Exercises Options, Realizes $754KBio-Techne (NASDAQ:TECH) - Benzinga
Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay Package - Yahoo Finance
Bio-Techne (TECH) director exercises options and delivers or withholds 5,559 shares for costs or taxes. - Stock Titan
Bio-Techne shareholders approve $11.3 billion merger with German Merck - AKM.RU
What Does Shareholder Approval Mean for Bio-Techne's (NASDAQ:TECH) Merck KGaA Deal? - Kalkine Media
Is Bio-Techne Stock Outperforming the Nasdaq? - finance.yahoo.com
Is Bio-Techne Stock Outperforming the Nasdaq? - barchart.com
Form 8K Bio-Techne Corp For: 23 September By Investing.com - Investing.com Canada
Form 8K Bio-Techne Corp For: 23 September - Investing.com India
Merck KGaA's USD 11.3b Bio-Techne acquisition clears final shareholder approval hurdle - AllSci
Bio-Techne (TECH) Opens Düsseldorf Hub As Fair Value Questions Come Into Focus - simplywall.st
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany - Investing News Network
Bio-Techne shareholders approve Merck KGaA acquisition - Investing.com
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany - PR Newswire
Bio-Techne Opens New Customer Experience Center in Germany - marketscreener.com
Bio-Techne Opens New Customer Experience Center in Germany - finance.yahoo.com
Bio-Techne opens customer experience center in Düsseldorf - Investing.com
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration - marketscreener.com
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration - Yahoo Finance
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration - Investing News Network
Bio-Techne Corp (TECH) Investor Outlook: Navigating Market Dynamics with a Focus on Growth Potential - DirectorsTalk Interviews
Why Is Techne (TECH) Down 0.1% Since Last Earnings Report? - Zacks Investment Research
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger – AUUD, TECH, CZR and CBAN - GlobeNewswire Inc.
Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others - Yahoo Finance UK
Bio-Techne Corp (TECH) Stock Analysis: Navigating Its Current Valuation and Growth Potential - DirectorsTalk Interviews
Bio-Techne Corp (NASDAQ: TECH) Share Price, TECH Stock News, TECH Share Price & Updates - Kalkine
Ademi LLP investigates Bio-Techne sale to Merck KGaA - scanx.trade
Global Multiplex Assays Market 2026 Edition Consumables Dominate Multiplex Assays with 68% Market Share - GlobeNewswire Inc.
Bio-Techne (TECH), What Is Behind The Latest Attention? - simplywall.st
TECH: Bio-Techne Corp Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals - marketscreener.com
Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals - Stock Titan
Bio-Techne Corp (TECH) Stock Analysis: Evaluating the Balance Between Growth Potential and Current Valuation - DirectorsTalk Interviews
Winners And Losers Of Q2: Bio-Techne (NASDAQ:TECH) Vs The Rest Of The Research Tools & Consumables Stocks - Yahoo Finance
Legal & General buys $19.51M stake in Bio-Techne - Dealroom
Bio-Techne Corp (TECH) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Bio-Techne To Be Acquired by Merck KGaA - Morningstar
BIO-TECHNE Corp FY 2026: Revenue $1.22B, EPS $1.16— 10-K Summary - TradingView
Bio-Techne draws fresh institutional cash as revenue climbs to $321M - app.dealroom.co
Bio-Techne Gives FTC More Time On $11.3B Merck Deal - Law360
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation? - TradingView
Bio-Techne (Nasdaq: TECH) investors to vote on Merck cash takeover - Stock Titan
Bio-Techne (NASDAQ: TECH) GC gets new RSU grants, no stock sales - Stock Titan
Bio-Techne (NASDAQ: TECH) grants CFO 22,438 and 36,459 RSUs - Stock Titan
Bio-Techne (TECH) director granted 1,381 RSUs vesting 2027-29 - Stock Titan
Bio-Techne (TECH) insider updates stock holdings - Stock Titan
바이오-테크네 (TECH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오-테크네 주식 (TECH) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BAUMGARTNER ROBERT V | Director |
Sep 22 '26 |
Option Exercise |
0.00 |
15,940 |
0 |
62,443 |
| Bohnen Shane | SVP - General Counsel |
Aug 15 '26 |
Option Exercise |
0.00 |
4,350 |
0 |
11,703 |
| Crouse Steven C. | President - Diag & Spatial Bi |
Aug 15 '26 |
Option Exercise |
0.00 |
5,423 |
0 |
12,184 |
| Herr Amy E. | Director |
Aug 15 '26 |
Option Exercise |
0.00 |
589 |
0 |
789 |
| Kelderman Kim | Chief Executive Officer |
Aug 15 '26 |
Option Exercise |
0.00 |
21,470 |
0 |
93,583 |
| Hippel James | CFO |
Aug 15 '26 |
Option Exercise |
0.00 |
9,779 |
0 |
174,493 |
| Geist William | PRESIDENT, PROTEIN SCIENCES |
Aug 15 '26 |
Option Exercise |
0.00 |
6,416 |
0 |
26,919 |
| Hippel James | CFO |
Jul 29 '26 |
Option Exercise |
47.60 |
62,068 |
2,954,437 |
215,738 |
| Kelderman Kim | Chief Executive Officer |
Jul 28 '26 |
Option Exercise |
47.60 |
35,000 |
1,666,000 |
100,799 |
| Bohnen Shane | SVP - General Counsel |
Jul 23 '26 |
Option Exercise |
47.60 |
448 |
21,325 |
7,697 |
4.81%
자본화:
|
볼륨(24시간):